M D Witham1, F Adams2, S McSwiggan2, G Kennedy2, G Kabir2, J J F Belch2, F Khan2. 1. Medical Research Institute, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, Scotland, UK. Electronic address: m.witham@dundee.ac.uk. 2. Medical Research Institute, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, Scotland, UK.
Abstract
BACKGROUND AND AIMS: Low 25-hydroxyvitamin D levels are common in patients with chronic fatigue syndrome; such patients also manifest impaired vascular health. We tested whether high-dose intermittent oral vitamin D therapy improved markers of vascular health and fatigue in patients with chronic fatigue syndrome. METHODS AND RESULTS: Parallel-group, double-blind, randomised placebo-controlled trial. Patients with chronic fatigue syndrome according to the Fukuda (1994) andCanadian (2003) criteria were randomised to receive 100,000 units oral vitamin D3 or matching placebo every 2 months for 6 months. The primary outcome was arterial stiffness measured using carotid-femoral pulse wave velocity at 6 months. Secondary outcomes included flow-mediated dilatation of the brachial artery, blood pressure, cholesterol, insulin resistance, markers of inflammation and oxidative stress, and the Piper Fatigue scale. As many as 50 participants were randomised; mean age 49 (SD 13) years, mean baseline pulse wave velocity 7.8 m/s (SD 2.3), mean baseline office blood pressure 128/78 (18/12) mmHg and mean baseline 25-hydroxyvitamin D level 46 (18) nmol/L. 25-hydroxyvitamin D levels increased by 22 nmol/L at 6 months in the treatment group relative to placebo. There was no effect of treatment on pulse wave velocity at 6 months (adjusted treatment effect 0.0 m/s; 95% CI -0.6 to 0.6; p = 0.93). No improvement was seen in other vascular and metabolic outcomes, or in the Piper Fatigue scale at 6 months (adjusted treatment effect 0.2 points; 95% CI -0.8 to 1.2; p = 0.73). CONCLUSION:High-dose oral vitamin D3 did not improve markers of vascular health or fatigue in patients with chronic fatigue syndrome. TRIAL REGISTRATION: www.controlled-trials.com, ISRCTN59927814.
RCT Entities:
BACKGROUND AND AIMS: Low 25-hydroxyvitamin D levels are common in patients with chronic fatigue syndrome; such patients also manifest impaired vascular health. We tested whether high-dose intermittent oral vitamin D therapy improved markers of vascular health and fatigue in patients with chronic fatigue syndrome. METHODS AND RESULTS: Parallel-group, double-blind, randomised placebo-controlled trial. Patients with chronic fatigue syndrome according to the Fukuda (1994) and Canadian (2003) criteria were randomised to receive 100,000 units oral vitamin D3 or matching placebo every 2 months for 6 months. The primary outcome was arterial stiffness measured using carotid-femoral pulse wave velocity at 6 months. Secondary outcomes included flow-mediated dilatation of the brachial artery, blood pressure, cholesterol, insulin resistance, markers of inflammation and oxidative stress, and the Piper Fatigue scale. As many as 50 participants were randomised; mean age 49 (SD 13) years, mean baseline pulse wave velocity 7.8 m/s (SD 2.3), mean baseline office blood pressure 128/78 (18/12) mmHg and mean baseline 25-hydroxyvitamin D level 46 (18) nmol/L. 25-hydroxyvitamin D levels increased by 22 nmol/L at 6 months in the treatment group relative to placebo. There was no effect of treatment on pulse wave velocity at 6 months (adjusted treatment effect 0.0 m/s; 95% CI -0.6 to 0.6; p = 0.93). No improvement was seen in other vascular and metabolic outcomes, or in the Piper Fatigue scale at 6 months (adjusted treatment effect 0.2 points; 95% CI -0.8 to 1.2; p = 0.73). CONCLUSION: High-dose oral vitamin D3 did not improve markers of vascular health or fatigue in patients with chronic fatigue syndrome. TRIAL REGISTRATION: www.controlled-trials.com, ISRCTN59927814.
Authors: Monica L Joustra; Isidor Minovic; Karin A M Janssens; Stephan J L Bakker; Judith G M Rosmalen Journal: PLoS One Date: 2017-04-28 Impact factor: 3.240
Authors: Albina Nowak; Lukas Boesch; Erik Andres; Edouard Battegay; Thorsten Hornemann; Christoph Schmid; Heike A Bischoff-Ferrari; Paolo M Suter; Pierre-Alexandre Krayenbuehl Journal: Medicine (Baltimore) Date: 2016-12 Impact factor: 1.889
Authors: Louise A Beveridge; Faisel Khan; Allan D Struthers; Jane Armitage; Ilaria Barchetta; Iain Bressendorff; Maria Gisella Cavallo; Robert Clarke; Rinkoo Dalan; Gavin Dreyer; Adam D Gepner; Nita G Forouhi; Ryan A Harris; Graham A Hitman; Thomas Larsen; Rajesh Khadgawat; Peter Marckmann; Frank H Mose; Stefan Pilz; Alexandra Scholze; Marina Shargorodsky; Seth I Sokol; Hans Stricker; Carmine Zoccali; Miles D Witham Journal: J Am Heart Assoc Date: 2018-05-30 Impact factor: 5.501
Authors: Ben Schöttker; Sabine Kuznia; Dana Clarissa Laetsch; David Czock; Annette Kopp-Schneider; Reiner Caspari; Hermann Brenner Journal: BMC Cancer Date: 2020-08-08 Impact factor: 4.430